Merit Medical Systems Inc
MMSI
$88.14
-1.79%
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures, operating primarily in the Medical - Instruments & Supplies industry. As a specialized player, Merit holds a distinct position with its focus on minimally invasive devices, serving a global market with a broad portfolio across two segments: Cardiovascular and Endoscopy. The current investor narrative centers on the company's strategic expansion into therapeutic oncology through the acquisition of View Point Medical, which is expected to drive long-term growth but will dilute earnings in the near term, creating a debate about the balance between immediate financial impact and future potential.…
MMSI
Merit Medical Systems Inc
$88.14
Related headlines
Investment Opinion: Should I buy MMSI Today?
Rating: Buy. Merit Medical is a solid growth company with a clear strategic direction, and the analyst consensus of 'buy' with an average target of $101.45 supports this view. The thesis is that the company's expansion into therapeutic oncology will drive long-term growth, and the current valuation, while not cheap, is reasonable given the forward PE of 19.43x.
Sign up to view all
MMSI 12-Month Price Forecast
The AI assessment is bullish on MMSI, driven by the company's strategic expansion into oncology, healthy margins, and a forward valuation that appears reasonable. The stock has strong momentum, and analyst sentiment is positive. However, the high PEG ratio and near-term earnings dilution from the acquisition warrant caution. The stance would be upgraded to high confidence if the company delivers strong earnings growth and the PEG ratio falls below 2, while a downgrade would occur if revenue growth decelerates or integration issues emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Merit Medical Systems Inc's 12-month outlook, with a consensus price target around $101.45 and implied upside of +15.1% versus the current price.
Average Target
$101.45
0 analysts
Implied Upside
+15.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$83 - $123
Analyst target range
Merit Medical is covered by 11 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 1.82 (where 1 is strong buy and 5 is sell). The average target price is $101.45, implying an upside of approximately 13.2% from the current price of $89.60. The target range spans from a low of $83.00 to a high of $123.00, with the high target suggesting potential for significant upside if the company executes on its growth strategy, while the low target reflects risks such as integration challenges or competitive pressures. The wide spread between the low and high targets indicates moderate uncertainty, but the overall bullish sentiment is supported by the buy recommendation and the fact that the average target is above the current price.
Drowning in data?
Find the real signal!
Bulls vs Bears: MMSI Investment Factors
Merit Medical presents a mixed picture: strong growth prospects from strategic acquisitions and healthy margins are offset by a high trailing valuation and recent underperformance versus the market. The bull case is supported by analyst consensus and forward PE of 19.43x, indicating expected earnings growth, while the bear case highlights near-term dilution and potential overextension. Currently, the bull side has stronger evidence given the positive analyst sentiment and growth trajectory, but the key tension lies in whether the company can execute on its oncology expansion to justify the valuation. If earnings growth materializes as expected, the stock has upside; if not, the high PEG ratio could lead to multiple compression.
Bullish
- Strong Revenue Growth Trajectory: Revenue is estimated at $2.07 billion annualized, with the company consistently growing through acquisitions and organic expansion. The 3-month price change of +38.96% reflects strong market confidence in this growth, supported by a 6-month change of +23.31%.
- Healthy Profitability and Margins: Gross margin stands at 48.65% and operating margin at 12.17%, indicating efficient cost management and a solid business model. Net margin of 8.48% shows the company is profitable, with positive net income and ROE of 8.11%.
- Analyst Consensus is Buy with Upside: 11 analysts rate MMSI a 'buy' with a mean recommendation score of 1.82 (strong buy territory). The average target price of $101.45 implies a 13.2% upside from the current price of $89.60, with a high target of $123.00 suggesting even greater potential.
- Strategic Expansion into Oncology: The acquisition of View Point Medical expands Merit's portfolio into therapeutic oncology, a high-growth market. This strategic move is expected to drive long-term growth, aligning with the company's focus on minimally invasive devices.
Bearish
- High Valuation on Trailing Earnings: The trailing PE of 40.62x is elevated, reflecting market expectations of high growth. However, the PEG ratio of 8.41x suggests the stock is expensive relative to its expected growth rate, which may limit upside if growth disappoints.
- Near-Term Earnings Dilution from Acquisition: The View Point Medical acquisition will dilute earnings in the near term, as noted in the news. This could pressure the stock if investors focus on short-term EPS rather than long-term potential.
- Underperformance vs. Market Over 1 Year: MMSI's 1-year price change is -2.77%, while the S&P 500 (SPY) gained 18.65% over the same period. This significant underperformance (relative strength -21.42%) suggests the stock has lagged the broader market, possibly due to sector rotation or company-specific issues.
- Potential Overextension Near 52-Week High: The stock trades at $89.60, near the 52-week high of $94.75 (94.6% of the high). After a 38.96% surge in 3 months, the stock may be overbought in the short term, risking a pullback.
MMSI Technical Analysis
Merit Medical's stock has experienced a robust recovery over the past year, with a 1-year price change of -2.77%, yet the current price of $89.60 sits near the top of its 52-week range, at approximately 94.6% of the high of $94.75 and 50% above the low of $59.74. This positioning near the highs indicates strong momentum and investor confidence, though it also suggests the stock may be overextended in the short term. The 6-month price change of +23.31% underscores a sustained uptrend, with the stock having recovered sharply from its 52-week low.
Beta
0.51
0.51x market volatility
Max Drawdown
-35.3%
Largest decline past year
52-Week Range
$60-$95
Price range past year
Annual Return
+11.0%
Cumulative gain past year
| Period | MMSI Return | S&P 500 |
|---|---|---|
| 1m | +2.1% | +1.8% |
| 3m | +20.7% | +3.1% |
| 6m | +25.7% | +10.9% |
| 1y | +11.0% | +17.3% |
| ytd | +2.0% | +14.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MMSI Fundamental Analysis
Merit Medical's revenue trajectory appears positive, with the most recent quarterly revenue estimated at $2.07 billion (annualized), and the company has been growing through acquisitions, such as the View Point Medical deal, which is expected to boost long-term growth. The gross margin stands at 48.65%, indicating a healthy level for the medical devices industry, while the operating margin is 12.17%, reflecting efficient cost management. Net income is positive, with a net margin of 8.48%, and the trailing EPS is $0.0246, though this is likely a quarterly figure; the company is profitable and generating solid returns.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MMSI Overvalued?
Given that Merit Medical has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 40.62x, while the forward PE is 19.43x, indicating that the market expects significant earnings growth, as the forward multiple is substantially lower. The PEG ratio of 8.41x suggests that the stock is expensive relative to its expected growth rate, but this may be skewed by near-term earnings dilution from acquisitions. Compared to the industry average (not provided), the stock's PS ratio of 3.44x and EV/Sales of 3.59x are typical for a medical devices company with growth prospects.
PE
40.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Merit Medical carries a moderate debt load with a debt-to-equity ratio of 0.57, which is manageable but could strain cash flows if interest rates rise. The company's net margin of 8.48% is solid, but the recent acquisition of View Point Medical will dilute earnings in the near term, potentially disappointing investors who focus on EPS. Revenue concentration in the Cardiovascular segment (majority of revenue) exposes the company to risks if that market faces headwinds or competitive pressures. Additionally, the high trailing PE of 40.62x implies that the market expects significant growth; any shortfall could lead to a sharp de-rating.